Scientific Industries (SCND) investor relations material

Executive summary

• Loss from continuing operations before income tax was $1,589,300 for Q1 2026, an improvement from a $2,057,100 loss in Q1 2025, driven by increased revenues and cost-cutting in Bioprocessing Systems and Corporate segments.

• Net revenues rose 30.2% year-over-year to $1,227,100, with growth in both Benchtop Laboratory Equipment and Bioprocessing Systems segments.

• Sale of the Genie Division in August 2025 resulted in discontinued operations, with ongoing revenue from related agreements.

Financial highlights

• Gross profit margin increased to 38.3% from 36.5% year-over-year, reflecting higher margin new products in Bioprocessing Systems.

• General and administrative expenses decreased 27.4% to $746,900 due to workforce reductions.

• Selling expenses fell 8.8% to $687,000, reflecting cost savings in sales and marketing.

• Research and development expenses increased 7.9% to $703,700, driven by new product development.

• Other income, net, rose to $78,400, mainly from higher interest income on investment securities.

• Net loss for Q1 2026 was $1,589,300, compared to $1,778,500 in Q1 2025.

• Basic and diluted loss per share from continuing operations was $(0.13) for Q1 2026.

Outlook and guidance

• Management expects cash generated from the Genie Division sale and related agreements to support operations for at least one year, but ongoing negative cash flows from operations are anticipated.

• Continued focus on cost reductions and revenue growth is necessary to maintain liquidity.